ATE173544T1 - Parvovirusrezeptoren und verfahren zur ihrer verwendung - Google Patents
Parvovirusrezeptoren und verfahren zur ihrer verwendungInfo
- Publication number
- ATE173544T1 ATE173544T1 AT94912271T AT94912271T ATE173544T1 AT E173544 T1 ATE173544 T1 AT E173544T1 AT 94912271 T AT94912271 T AT 94912271T AT 94912271 T AT94912271 T AT 94912271T AT E173544 T1 ATE173544 T1 AT E173544T1
- Authority
- AT
- Austria
- Prior art keywords
- parvovirus
- methods
- binding
- sample
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/034,132 US5449608A (en) | 1993-03-22 | 1993-03-22 | Parvovirus B19 receptor and parvovirus B19 detection |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE173544T1 true ATE173544T1 (de) | 1998-12-15 |
Family
ID=21874512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT94912271T ATE173544T1 (de) | 1993-03-22 | 1994-03-22 | Parvovirusrezeptoren und verfahren zur ihrer verwendung |
Country Status (8)
Country | Link |
---|---|
US (1) | US5449608A (de) |
EP (1) | EP0690990B1 (de) |
JP (1) | JPH08511865A (de) |
AT (1) | ATE173544T1 (de) |
AU (1) | AU6449694A (de) |
CA (1) | CA2158564A1 (de) |
DE (1) | DE69414700D1 (de) |
WO (1) | WO1994022014A1 (de) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2755817B2 (ja) * | 1988-11-14 | 1998-05-25 | アメリカ合衆国 | パルボウイルスキャプシド |
ATE427488T1 (de) * | 1995-06-07 | 2009-04-15 | Progenics Pharm Inc | Monoklonaler antikírper fur die inhibierung von hiv-1-hullgykoprotein-vermittelte membranfusion |
JPH0910000A (ja) * | 1995-06-26 | 1997-01-14 | Nippon Sekijiyuujishiya | ヒトパルボウイルスの検出方法及びそのための試薬 |
US7118859B2 (en) | 1996-01-17 | 2006-10-10 | Progenics Pharmaceuticals, Inc. | Methods for inhibiting HIV-1 infection |
US7858298B1 (en) | 1996-04-01 | 2010-12-28 | Progenics Pharmaceuticals Inc. | Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists |
US6344545B1 (en) * | 1996-06-14 | 2002-02-05 | Progenics Pharmaceuticals, Inc. | Method for preventing HIV-1 infection of CD4+ cells |
US20040086528A1 (en) * | 1996-06-14 | 2004-05-06 | Progenics Pharmaceuticals, Inc. | Uses of a chemokine receptor for inhibiting HIV-1 infection |
US6528098B2 (en) * | 1996-10-22 | 2003-03-04 | Advanced Viral Research Corp. | Preparation of a therapeutic composition |
US5973128A (en) * | 1996-11-22 | 1999-10-26 | The Hospital For Sick Children Research And Development Lp | Glycolipid mimics and methods of use thereof |
US6268349B1 (en) * | 1997-04-15 | 2001-07-31 | Advanced Viral Research Corp. | Method for treating B19 parvovirus infections |
US6238860B1 (en) | 1998-11-05 | 2001-05-29 | Dyax Corp. | Binding moieties for human parvovirus B19 |
US20040228869A1 (en) * | 1998-12-16 | 2004-11-18 | Progenics Pharmaceuticals, Inc. | Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto |
US20080015348A1 (en) * | 1998-12-16 | 2008-01-17 | Progenics Pharmaceuticals, Inc. | Nucleic acids encoding polypeptides of anti-CCR5 antibodies |
US7138119B2 (en) * | 2000-09-15 | 2006-11-21 | Progenics Pharmaceuticals, Inc. | Compositions and methods for inhibition of HIV-1 infection |
US7060273B2 (en) * | 2001-04-06 | 2006-06-13 | Progenics Pharmaceuticals, Inc. | Methods for inhibiting HIV-1 infection |
MXPA03011802A (es) | 2001-06-28 | 2004-04-02 | Chiron Corp | Ensayo de diagnostico para parvovirus b19. |
EP1421095B1 (de) | 2001-08-31 | 2013-10-09 | Gen-Probe Incorporated | Assay zum nachweis der nukleinsäure des humanen parvovirus b19 |
US7122185B2 (en) * | 2002-02-22 | 2006-10-17 | Progenics Pharmaceuticals, Inc. | Anti-CCR5 antibody |
EP1799856A4 (de) * | 2004-09-10 | 2009-03-04 | Focus Diagnostics Inc | Verfahren und zusammensetzungen zum nachweis von erythrovirus-genotypen |
US20090305944A1 (en) * | 2005-06-03 | 2009-12-10 | Bbm Holdings, Inc | Methods for Providing Palliative Care with AVR 118 |
US8227583B2 (en) | 2007-06-14 | 2012-07-24 | The Board Of Regents For Oklahoma State University | Vaccines containing canine parvovirus genetic variants |
SG182206A1 (en) * | 2007-06-14 | 2012-07-30 | Univ Oklahoma State | Vaccines containing canine parvovirus genetic variants |
WO2009117615A2 (en) | 2008-03-20 | 2009-09-24 | Blood Systems, Inc. | Novel divergent picornavirus:cosavirus |
AU2010217928B2 (en) | 2009-02-26 | 2013-06-06 | Gen-Probe Incorporated | Assay for detection of human parvovirus nucleic acid |
ES2945966T3 (es) | 2011-07-15 | 2023-07-11 | Gen Probe Inc | Composiciones y procedimiento para detectar ácido nucleico del parvovirus humano y ácido nucleico del virus de la hepatitis A |
-
1993
- 1993-03-22 US US08/034,132 patent/US5449608A/en not_active Expired - Lifetime
-
1994
- 1994-03-22 CA CA002158564A patent/CA2158564A1/en not_active Abandoned
- 1994-03-22 JP JP6521286A patent/JPH08511865A/ja active Pending
- 1994-03-22 AT AT94912271T patent/ATE173544T1/de not_active IP Right Cessation
- 1994-03-22 DE DE69414700T patent/DE69414700D1/de not_active Expired - Lifetime
- 1994-03-22 AU AU64496/94A patent/AU6449694A/en not_active Abandoned
- 1994-03-22 WO PCT/US1994/003009 patent/WO1994022014A1/en active IP Right Grant
- 1994-03-22 EP EP94912271A patent/EP0690990B1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE69414700D1 (de) | 1998-12-24 |
US5449608A (en) | 1995-09-12 |
EP0690990B1 (de) | 1998-11-18 |
EP0690990A1 (de) | 1996-01-10 |
CA2158564A1 (en) | 1994-09-29 |
AU6449694A (en) | 1994-10-11 |
JPH08511865A (ja) | 1996-12-10 |
WO1994022014A1 (en) | 1994-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE173544T1 (de) | Parvovirusrezeptoren und verfahren zur ihrer verwendung | |
ATE377657T1 (de) | Serpin-arzneistoffe zur behandlung einer hiv- infektion und verfahren zu deren verwendung | |
PL374311A1 (en) | Methods for purifying protein | |
ATE266675T1 (de) | Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese | |
DE60130538D1 (de) | Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung | |
DE60039752D1 (de) | Herstellung tetravalenter antikörper | |
ATE279181T1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
ATE287948T1 (de) | Plasmide dna reinigung durch peg-fällung und säulen-chromatographie | |
ATE153704T1 (de) | Anti-t-zell rezeptordeterminanten zur behandlung von autoimmunkrankheiten | |
ATE186900T1 (de) | Verfahren zur aeroben, weitergehenden biologischen reinigung von abwässern | |
SE8205244L (sv) | Medel for avlegsnande av mikroorganismer fran vevnader | |
BR9916209A (pt) | Cadeia de receptor de citocina | |
DE69509843D1 (de) | Apparat zur Behandlung z.B. von Poststücken | |
ATE368110T1 (de) | Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten | |
ATE484294T1 (de) | Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen | |
ATE254128T1 (de) | Substituierte tricyclische verbindungen und deren verwendung zur behandlung von spla2-bedingten erkrankungen | |
DK0749481T3 (da) | Humaniserede monoklonale antistoffer mod human interleukin-4 | |
ATE173620T1 (de) | Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs | |
DE69433243D1 (de) | Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit | |
EP0871457A4 (de) | Isolierte stromazellen und methoden zu deren verwendung | |
ATE191568T1 (de) | Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine | |
MXPA02005236A (es) | Metodos de tratamiento de lupus con base en la afinidad de anticuerpos y metodos de separacion por exclusion y composiciones para el uso de los mismos. | |
EP0960937A4 (de) | Neues semaphorin-gen: semaphorin y | |
ATE175212T1 (de) | Cai-resistenzproteine kodierende dna, und ihre verwendung | |
DE69621915D1 (de) | Anti-dns-antikörpernachweis mittels erkennung und bindung telomerischer dns-sequenzen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |